There is a significant need for a minimally invasive, cost-effective and reliable method to diagnose early-stage Alzheimer disease. Building on previous work, Nakamura et al. demonstrate the use of immunoprecipitation coupled with mass spectrometry to measure plasma amyloid-β (Aβ) biomarkers. Using two independent data sets, which included cognitively normal individuals and individuals with mild cognitive impairment or Alzheimer disease, they demonstrate that plasma amyloid-β precursor protein (APP)669–711/Aβ1–42 and Aβ1–40/Aβ1–42 ratios, and their composites, can accurately predict brain Aβ burden.
References
Nakamura, A. et al. High performance plasma amyloid-β biomarkers for Alzheimer's disease. Nature 544, 249–254 (2018)
Rights and permissions
About this article
Cite this article
Crunkhorn, S. Identification of blood-based biomarkers. Nat Rev Drug Discov 17, 166 (2018). https://doi.org/10.1038/nrd.2018.32
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.32